Published in Drug Week, March 30th, 2007
Epibase(R) is applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines. The patent relates to AlgoNomics' method to identify T-cell epitopes through the physicochemical interactions of the epitopes with their HLA Class-I and Class-II receptors.
Philippe Stas, COO of AlgoNomics: "We provide the state of the art in modeling of proteins, and this patent confirms our pioneering role in the field...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.